Killer cell immunotherapy can treat advanced pancreatic cancer

Share This Post

Researchers at the University of New South Wales in Sydney and the California Institute of Biomedicine (CALIBR) have demonstrated that “specially cultured killer cells” can be used to treat pancreatic cancer. In the study, the team obtained pancreatic cancer cells from patients with advanced pancreatic cancer and transplanted them into mice. Then modify the patient’s immune cells to specifically recognize and eliminate cancer cells, which is why they are also called specially cultured killer cells or CAR-T cells. After these CAR-T cells were injected into mice, they were able to find all cancer cells in the body, adhere to them through surface markers, and then destroy the cancer cells. The therapeutic effect is very significant, and the cancer cells in the mice disappear completely, including cancer cells that have spread to the liver and lungs. This landmark study was recently published in the top academic journal Gut.

The researchers not only demonstrated the effectiveness of the new CAR-T immunotherapy for pancreatic cancer. At the same time, a new technology was introduced to help them fully control the activity of CAR-T cells. Using so-called “switchable CAR-T cells,” the team used this new concept in pancreatic cancer for the first time and divided cancer target recognition and subsequent cancer cell killing into two separate processes. Dr. Alexandra Aicher, co-corresponding author of the University of New South Wales School of Medicine, said that CAR-T cell therapy is very powerful but requires careful manipulation.

The team now hopes to bring this promising therapy to the clinic and is seeking funding to make progress. Professor Chris Heeschen, lead author of the University of New South Wales School of Medicine, said that the next step is to combine CAR-T cells with treatment to make CAR-T cells reach cancer cells more easily.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy